15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
22:01 , Jun 17, 2019 |  BC Extra  |  Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
23:37 , Mar 26, 2019 |  BC Extra  |  Company News

Management tracks: Rubius, Abingworth, Arcus

Rubius hired Greg Whitehead as SVP and chief quality officer, a newly created position. He was VP, quality at bluebird bio Inc. (NASDAQ:BLUE). Whitehead will be responsible for defining the company's quality strategy to meet...
18:46 , Feb 15, 2019 |  BC Week In Review  |  Financial News

TCR2 raises $75M in IPO

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced Feb. 13. The immuno-oncology company priced 5 million shares at $15, the midpoint of its proposed range of $14-$16. The price valued TCR2 at...
05:02 , Feb 14, 2019 |  BC Extra  |  Financial News

TCR2 prices $75M IPO at midpoint

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced late Wednesday. The company added $0.07 to $15.07 in its first day of trading Thursday. The immuno-oncology company priced 5 million shares at $15,...
23:22 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched on Feb. 7 with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first...
21:56 , Feb 7, 2019 |  BC Extra  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched Thursday with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first company exclusively...